Equity Profile

SYRE

Spyre Therapeutics, Inc.

Health CareBiotechnology$8.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth to gauge market demand for Spyre's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, it plays a crucial role in advancing medical treatments that could significantly impact patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In the last quarter, Spyre reported an EPS of -$0.74, which was worse than the expected -$0.66. The stock saw a modest increase of 2.72% the following day, indicating some investor optimism despite the miss.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to improving operational efficiency.
Plans to enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Spyre has a history of both beating and missing EPS estimates. Investors are particularly interested in any updates regarding clinical trials and revenue growth.

Bull Case

If Spyre can demonstrate significant progress in its clinical trials and show revenue growth, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it could lead to a negative reaction and further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and their expected timelines?

The market will closely watch for updates on clinical trials, as these can significantly impact future revenue and investor confidence.

What revenue growth can be expected in the upcoming quarters?

Investors will be looking for concrete figures or guidance on revenue growth to assess the company's market position and potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new clinical trial results that could lead to accelerated product approvals.

Supporting Evidence

Historical performance shows that the company has a 63% EPS beat rate, indicating potential for positive surprises.

The options market is pricing a larger move than historical averages, suggesting heightened expectations for volatility.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Spyre's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

Demonstrating a clear path to profitability with EPS improving to -$0.50 or better.

Bear Confirmed If

Reporting an EPS worse than -$0.80, indicating deeper financial issues.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations, history suggests a potential stock increase of around 1.37%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors digest the information.

Miss

Should the company miss expectations, history indicates a likely decline of about 2.20%, reflecting negative investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any guidance on expected revenue growth for the next quarter.
3Management's commentary on cost management strategies.
4Insights into partnerships or collaborations that may enhance product development.
5Responses to analyst questions regarding market competition and positioning.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth to gauge market demand for Spyre's products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SYRE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to improving operational efficiency.
Plans to enhance partnerships with research institutions.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Spyre has a history of both beating and missing EPS estimates. Investors are particularly interested in any updates regarding clinical trials and revenue growth.

Bull Case

If Spyre can demonstrate significant progress in its clinical trials and show revenue growth, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company reports wider losses or delays in clinical trials, it could lead to a negative reaction and further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and their expected timelines?

The market will closely watch for updates on clinical trials, as these can significantly impact future revenue and investor confidence.

What revenue growth can be expected in the upcoming quarters?

Investors will be looking for concrete figures or guidance on revenue growth to assess the company's market position and potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new clinical trial results that could lead to accelerated product approvals.

Supporting Evidence

Historical performance shows that the company has a 63% EPS beat rate, indicating potential for positive surprises.

The options market is pricing a larger move than historical averages, suggesting heightened expectations for volatility.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Spyre's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

Demonstrating a clear path to profitability with EPS improving to -$0.50 or better.

Bear Confirmed If

Reporting an EPS worse than -$0.80, indicating deeper financial issues.

Pre-Earnings Positioning

Options Market

Implied Move

±9.38%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±9.4% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (0)P/C Ratio: 4.00Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats expectations, history suggests a potential stock increase of around 1.37%, confirming positive market sentiment.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors digest the information.

Miss

Should the company miss expectations, history indicates a likely decline of about 2.20%, reflecting negative investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Any guidance on expected revenue growth for the next quarter.
3Management's commentary on cost management strategies.
4Insights into partnerships or collaborations that may enhance product development.
5Responses to analyst questions regarding market competition and positioning.